Summary
Radioimmunoimaging and radioimmunotherapy with radioiodinated anti-(hepatocellular carcinoma ferritin) antibody (131I-or125I-FtAb) have been applied in patients with primary liver cancer. A total of 41 patients with surgically unresectable hepatocellular carcinoma (HCC) and receiving hepatic artery ligation and cannulation during exploratory laparotomy were treated with this regimen by intrahepatic arterial infusion. Compared with the control group, a decline of serum α-fetoprotein (65.7% versus 42.9%) and shrinkage of tumor (68.3% versus 33.9%) were observed in the treated group, and a higher second-look resection rate (31.7% versus 5.1%) and longer survival (1-year: 61.0% versus 37.3%, 3-year: 25.0% versus 6.9%) resulted. The administration of antibody through a hepatic arterial catheter (n=16) was compared with intravenous injection (n-17) in terms of the tumor-imaging sensitivity in 33 patients with liver cancer. The results indicated that hepatic arterial infusion was superior to intravenous injection. The sensitivity 7 days after the administration was 100% in the i.a. group and 76.5% in the i.v. group, the uptake ratio of tumor to liver being 1.74±0.57 in the former and 1.34±0.29 in the latter. Furthermore, intrahepatic arterial infusion revealed a lower anti-antibody detection rate than intravenous injection (0/14 versus 4/11).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- AFP:
-
α-tetoprotein
- FtAb:
-
ferritin antibody
References
Beatty BG, O'Connor-Tressel M, Do T, Paxton RJ, Beatty JD (1990) Mechanism of decreasing liver uptake of111In-labeled anti-carcinoembryonic antigen monoclonal antibody by specific antibody pretreatment in tumor bearing mice. Cancer Res 50:846–851
Carrasquillo JA, Sugarbaker P, Colcher D, Reynolds JC, Esteban J, Bryant G, Keenan AM, Perentesis P, Yokoyama K, Simpson DE, Ferroui P, Farkas R, Schlom J, and Larson SM (1988) Radioimmunoscintigraphy of colon cancer with iodine-131-labeled B72.3 monoclonal antibody. J Nucl Med 29:1022–1033
Cobb LM, Humm JL (1986) Radioimmunotherapy of malignancy using antibody targeted radionuclides. Br J Cancer 54:863–870
Courtenay-Luck N, Epenetos AA, Moore R, Larche M, Pectaside D, Dhokia B, Ritter MA (1986) Development of primary and secondary immune response to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neaplasms. Cancer Res 46:6489–6493
Dykes PW, Bradwell AR, Chapman CE, Vaughan ATM (1987) Radioimmunotherapy of cancer: clinical studies and limiting factors. Cancer Treat Rev 14:87–106
Epenetos AA, Kosmas C (1989) Monoclonal antibodies for imaging and therapy. Br J Cancer 59:152–155
Fu KK, Rayner PA, Lam KN (1984) Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion. Int J Radiat Oncol Biol Phys 10:1473–1478
Fu KK, Lam KN, Rayner PA (1985) The influence of cis-platinum administration and low dose irradiation (CLDRI) on their combined effects on a murine squamous cell carcinoma. Int J Radiat Oncol Biol Phys 11:2119–2124
Goldenberg DM, Deland F, Kim E, Bennet S, Primus FJ, Nagell JR van Jr, Estes N, DeSimone P, Rayburn P (1978) Use of radiolabeled antibodies to carconoembryonic antigen for the detection and localization of diverse cancers by photoscanning. N Engl J Med 298:1384–1388
Halpern SE, Dillman RO (1987) Problems associated with radioimmunodetection and possibilities for future solutions. J Biol Response Mod 6:235–262
Jain RK (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res [Suppl] 50:814–819
Liu AY, Robinson RR, Hellström KE, Murray ED Jr, Chang CP, Hellström I (1987a) Chimetric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA 84:3439–3443
Liu AY, Robinson RR, Murray ED Jr, Ledbetter JA, Hellström I, Hellström KE (1987b) Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol 139:3521–3526
Liu KD, Tang ZY, Bao YM, Lu JZ, Qian F, Yuan AN, Zhao HY (1989) Radioimmunotherapy for hepatocellular carcinoma (HCC) using131I anti-HCC isoferritin IgG: preliminary results of experimental and clinical studies. Int J Radiat Oncol Biol Phys 16:319–323
Matzku S, Tilgen W, Kalthoff H, Schmiegel WH, Brocker E-B (1988) Dynamics of antibody transport and internalization. Int J Cancer [Suppl] 2:11–14
Moroz C, Lantsberg Z, Sela O, Cohen Y, Khodadadi J, Goldstein J, Quastel MR, Shoenfeld Y (1989) Radioimmunodetection of tumors with monoclonal antiplacental ferritin antibody: preliminary results. Oncology 46:35–39
Order SE, Stillwagon GB, Klein JL, Leichner PK, Siegelman SS, Fishman EK, Ettinger DS, Haulk T, Kopher KA, Finney K, Surdyke M, Selt S, Leibel S (1985)131I antiferritin, a new treatment modality in hepatoma: an RTOG study. J Clin Oncol 3:1573–1582
Order SE, Klein JL, Leichner PK (1987) Hepatoma: model for radiolabeled antibody in cancer treatment. NCI Monogr 3:37–41
Parker BA, Vasso AB, Halpern SE, Miller RA, Hupf H, Amox DG, Simoni JL, Starr RJ, Green MK, Royston I (1990) Radioimmunotherapy of human B-cell lymphoma with90Y conjugated antiidiotype monoclonal antibody. Cancer Res [Suppl] 50:1022–1028
Pressman D (1957) Radiolabeled antibodies. Proc Natl Acad Sci USA 69:644–650
Pressman D, Korngold L (1953) The in vivo localization of anti-Wagner osteogenic sarcoma antibodies. Cancer 6:619–623
Schlom J, Hand PH, Greiner JW, Colcher D, Shrivastav S, Carrasquillo JA, Reynolds JC, Larson SM, Raubitschek A (1990) Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. Cancer Res [Suppl] 50:820–827
Stickney DR, Slater JB, Kirk GA, Ahlem C, Chang C-H, Frincke JM (1989) Bifunctional antibody: ZCE/CHA111indium BLEDTA-IV clinical imaging in colorectal carcinoma. Antibody Immunoconj Radiopharmacol 2:1–13
Stewart JSW, Hird V, Snook D, Sullivan M, Hooker G, Courtenay-Luck N, Sivolapenko G, Griffiths M, Myers MJ, Lambert HE, Munro AJ, Eppentos AA (1989) Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity and efficacy of I-131 labeled monoclonal antibodies. Int J Radiat Oncol Biol Phys 16:405–413
Tang ZY (1989) Effects in the past decades to improve the ultimate outcome of primary liver cancer. In: Tang ZY, Wu MC, Xia SS (eds) Primary liver cancer. Springer, Berlin Heidelberg New York pp 469–481
Tang ZY, Liu KD, Guo YD, Ma ZC, Yu D, Yu ZY, Bao YM, Lu JZ, Lin ZY, Yu YQ, Zhao HY, Chen KJ, Qian F, Yuan AN, Wu ZM (1986) Tumor imaging and target therapy for hepatocellular carcinoma — preliminary results of experimental and clinical studies. Chin Med J 99:855–860
Tang ZY, Liu KD, Bao YM, Lu JZ, Yu YQ, Ma ZC, Zhou XD, Yang R, Gan YH, Lin ZY, Fan Z, Hou Z (1990) Radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma with reference to second look resection. Cancer 65:211–215
Tang ZY, Yu YQ, Zhou XD, Ma ZC, Lu JZ, Liu KD, Lin ZY, Yang BH, Fan Z, Hou Z, Zhang M (1991a) Cytoreduction and sequential resection: a hope for unresectable primary liver cancer. J Surg Oncol 47:27–31
Tang ZY, Zhou HY, Zhao G, Chai LM, Zhou M, Lu JZ, Liu KD, Havas HF, Nauts HC (1991b) Preliminary result of mixed bacterial vaccine as adjuvant treatment of hepatocellular carcinoma. Med Oncol Tumor Pharmacother 8:23–28
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fan, Z., Tang, Z., Liu, K. et al. Radioiodinated anti-hepatocellular carcinoma (HCC) ferritin Targeting therapy, tumor imaging and anti-antibody response in HCC patients with hepatic arterial infusion. J Cancer Res Clin Oncol 118, 371–376 (1992). https://doi.org/10.1007/BF01294442
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01294442